The cholinesterase inhibitors (ChEIs), galantamine, donepezil and rivastigmine, remain the predominant treatment for providing symptomatic relief for patients with mild-to-moderate Alzheimer’s disease (AD). Here, BCHE is linked to Alzheimer disease.